Related Experiment Video

Updated: Apr 7, 2026

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence
04:56

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence

Published on: December 30, 2025

336

Combining intracellular antibodies to restore function of mutated p53 in cancer

Grace Chan1, Gwen Jordaan1, Robert N Nishimura1,2

  • 1Department of Research, Veterans Affairs Greater Los Angele Healthcare System, Sepulveda, CA.

International Journal of Cancer
|July 16, 2015
PubMed

Insights

This study introduces a novel antibody therapy targeting the TP53 tumor suppressor gene. Combining two engineered antibodies, 3E10-PAb421 and 3E10-3G5, significantly enhances cancer cell growth inhibition in TP53-mutated cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunotherapy

Background:

  • TP53 is a critical tumor suppressor gene frequently mutated in human cancers.
  • Mdm2 regulates p53 stability and function within the cell nucleus.
  • Nuclear targeting for cancer therapy is challenging for conventional antibodies.

Purpose of the Study:

  • To develop and evaluate a novel antibody-based intranuclear delivery system for cancer therapy.
  • To assess the synergistic efficacy of combined bispecific antibodies targeting p53 and Mdm2.
  • To investigate the therapeutic potential in cancer cells with specific TP53 mutation statuses.

Main Methods:

  • Engineering of bispecific single-chain Fv (scFv) fragments using a cell-penetrating anti-DNA antibody (mAb 3E10) as a nuclear transport system.
  • Development of 3E10-PAb421 to bind and restore function to mutated p53.
  • Development of 3E10-3G5 to bind Mdm2 and inhibit p53 degradation.

Main Results:

  • Combination therapy with 3E10-PAb421 and 3E10-3G5 demonstrated augmented cancer cell growth inhibition compared to individual antibodies.
  • The enhanced therapeutic effect was observed specifically in cancer cells with TP53 mutations.
  • No significant enhanced response was noted in cancer cells with wild-type or null TP53.

Conclusions:

  • The engineered bispecific antibody system effectively delivers therapeutic payloads into the nucleus.
  • Combination therapy targeting both p53 and Mdm2 via the 3E10 platform shows promise for treating TP53-mutated cancers.
  • This approach offers a potential strategy for overcoming therapeutic limitations in nuclear-targeted cancer treatments.
Keywords:
Mdm2antibodiescanceroncogenep53tumor suppressor

More Related Videos

Purification of Ubiquitinated p53 Proteins from Mammalian Cells10:55

Purification of Ubiquitinated p53 Proteins from Mammalian Cells

Published on: March 21, 2022

2.9K
Yeast As a Chassis for Developing Functional Assays to Study Human P5314:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

10.2K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
3.4K
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
10.4K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
9.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
39.0K